The discovery of UofL School of Dentistry researcher David Scott, PhD, and his team recently published on-line first in the journal Molecular Medicine. The finding not only has implications in preventing periodontal disease, a chronic inflammatory disease that causes tooth loss, but also may have relevance to other chronic inflammatory diseases. Since GSK3b is involved in multiple inflammatory signaling pathways, it is associated with a number of diseases and also is being tested by scientists for its impact in Alzheimer's disease, Type II diabetes and some forms of cancer, to name a few.
"The traditional approach to dealing with periodontal disease is to prevent plaque from forming at the gum-line or prevent the consequences of periodontal disease progression," Scott said. "Our approach manipulates a natural mechanism within our bodies to prevent inflammation and subsequent degradation when exposed to the bacterium P. gingivalis."
GSK3b is known to facilitate the inflammation that occurs during bacterial infections, so blocking this enzyme from completing its normal function by using the GSK3-specific inhibitor, SB216763 stopped the inflammation process and subsequent bone loss induced by the key periodontal pathogen, P. gingivalis, Scott said.
The next step is for Scott and his team to determine whether SB216763 has any side-effects or whether they need to search for a different inhibitor of GSK3b.
Source: Science Daily